What the FDA Peptide Panel Actually Voted On

On 23 and 24 July 2026, an FDA advisory panel spent two days voting on seven peptides, and a great many of the headlines that followed got the story wrong. The panel did not approve anything. It voted on a narrow, technical question: whether each substance belongs on a list that governs what compounding pharmacies may legally use as a starting ingredient. That is a real regulatory event with real consequences, but it is not the same thing as a medicine reaching the market, and the gap between those two ideas is where almost all of the confusion lives. What follows is a date-stamped record of what was actually asked, how each of the seven votes landed, what the agency's own scientists had written beforehand, and what changes on the ground as a result, which for the moment is nothing at all.^{[1, 2]}

What the panel voted on, and what it did not

The panel is the Pharmacy Compounding Advisory Committee, a standing body that gives the FDA outside expert advice. Its role is advisory only: the agency's own meeting notice states that advisory committees make non-binding recommendations, which it generally follows but is not legally bound to adopt. The question in front of the committee was printed in the meeting's own paperwork, and it repays reading literally. For each substance it asked simply whether it should be placed on the list. The list in question is the 503A Bulks List. Nothing in that wording asks whether a peptide works, whether it is safe enough to sell as a medicine, or whether it should become an approved drug, and the committee did not approve a single peptide. Each substance was also split into two separate ballots, one for the free base form and one for the acetate salt, so the seven peptides produced fourteen votes in total.^{[1, 2]}

What the 503A bulks list actually is

Section 503A of the federal drug law governs traditional compounding by state-licensed pharmacists and physicians. Under it, a compounder may only start from a bulk substance in one of three situations: the substance complies with a United States Pharmacopeia or National Formulary monograph; or it is a component of a drug the FDA has already approved; or it appears on the 503A Bulks List. None of these seven peptides has its own monograph and none is a component of an approved medicine, which is precisely why the list route is the only door open to them. Inclusion is therefore a compounding-eligibility decision, not approval of a medicine, and the panel did not approve any substance for sale. The list is also not new or improvised: a final rule in February 2019 placed six substances on it and set the criteria, and a proposed rule from September 2019 is still working its way through public comments.^[3]

The scorecard: how all seven votes landed

Every peptide was balloted twice, once as free base and once as acetate, and both forms of each substance went the same way. A yes vote is a recommendation to add that substance to the 503A Bulks List; it is not a finding that the peptide works, and it did not approve anything for sale. One deliberate omission before the list: this page reports the direction of each vote and not the numeric tally. FDA has published no minutes for this meeting, and the trade-press accounts written up afterwards do not agree with one another on the counts. For more than one substance the reported split differs between outlets, and at least one widely repeated tally could not be confirmed against any second source. Until the agency publishes its own record, a specific vote count quoted for this meeting is unverified, so none appears below. The direction of each vote is the part that carries the consequence, and that much is not in dispute.^{[1, 2]}

BPC-157, KPV, TB-500 and MOTS-c: four yes votes on day one

The agenda for 23 July put four substances to the committee, and the committee voted in favor of all four. BPC-157 was evaluated for ulcerative colitis. KPV was evaluated for wound healing and inflammatory conditions, and TB-500 for wound healing. MOTS-c, the fourth substance heard that day, was evaluated for obesity and osteoporosis. All four are now recommended for addition to the 503A Bulks List, and in each case the free base and the acetate salt were balloted separately and went the same way. Those uses are worth dwelling on. The committee was asked about compounding these substances for specific medical indications, not about the general recovery and wellness uses that dominate the consumer market. A yes vote on BPC-157 for ulcerative colitis says nothing whatsoever about a vial bought online for a sore shoulder, and anyone citing the meeting as vindication of that second use is stretching the record well past what it says. Our standing read of the evidence at /verdicts/bpc-157 is unchanged by this meeting, because a compounding-eligibility vote is not new evidence about what the compound does.^{[1, 2, 4, 5, 6]}

Epitalon and Semax: two more yes votes on day two

Day two, 24 July, took the remaining three substances. Epitalon, evaluated for insomnia, and Semax, evaluated for cerebral ischemia, migraine and trigeminal neuralgia, were both recommended for the list; the committee voted in favor of adding each of them, again in both the free base and the acetate form. The third substance heard that day is the exception covered in the next section. Semax and Epitalon deserve a flag for a different reason: both are long-standing Russian-market compounds whose research base is largely non-Western, older, and difficult to audit from outside, which is exactly the sort of evidence gap the agency's reviewers spent their written packages describing. A favorable vote does not make that literature any easier to verify than it was the week before.^{[1, 2, 7, 8, 9]}

Emideltide (DSIP): the only no vote

Emideltide, better known as delta sleep-inducing peptide or DSIP, was the single substance the committee declined to recommend. It was heard on day two, and the committee voted against adding it to the list. It had been evaluated for opioid withdrawal, chronic insomnia and narcolepsy. The written reviewer position was blunt about the reasoning: the available data were thin, and there are already approved prescription medicines for all three of those conditions, which are serious and, in the case of opioid withdrawal, potentially life-threatening. That combination of existing licensed options plus weak supporting evidence is what tipped this one the other way. It is a useful illustration of how the criteria work in practice, because the bar rises when the condition is severe and established medicines already exist.^{[1, 2, 10]}

Why FDA's own scientists said no to all seven

The most striking feature of this meeting is that the committee broke with the agency's own reviewers on six of the seven substances. Staff prepared a detailed briefing package for each peptide, and in all seven the written conclusion was the same: the evaluation criteria weigh against placing the substance on the 503A Bulks List. Those criteria are four questions. Is the substance well characterized, physically and chemically? Has it been used historically in compounding? What evidence of effectiveness exists for products compounded with it? And are there safety concerns? Across the seven packages the recurring findings were an absence of human effectiveness data, sparse or unverifiable histories of compounding use, and safety information too limited to judge. The committee heard those conclusions and voted the other way six times. That disagreement is genuinely notable, but it did not approve a peptide, and the FDA has not approved any of these substances as a drug.^{[4, 5, 6, 7, 8, 9, 10]}

What happens next, and what has not changed

A recommendation is the beginning of a process, not the end of one. For any of these substances to actually reach the 503A Bulks List, the agency must run formal notice-and-comment rulemaking: a proposed rule, a public comment window, then a final rule. That machinery historically runs long. The current list itself emerged from a final rule in February 2019, and the proposed rule issued in September 2019 is still unfinished years later, which is a fair guide to the timescale involved here. Until a final rule says otherwise, none of these seven peptides is on the list, and the FDA has not approved any of them for any use. Compounding pharmacies stand in exactly the position they occupied on 22 July. Anything sold to consumers today on the strength of this vote is being sold ahead of the rule rather than because of it.^{[1, 3]}

What this does not mean if you are buying peptides

Three things follow from the record above, and they matter rather more than the headline did. First, a yes vote concerns pharmacy compounding, not retail: it is about what a state-licensed pharmacist may compound for an individual patient under a prescription, and it says nothing about vials sold online as research chemicals, a separate channel described as it actually operates in our guide at /learn/gray-market-peptides. Second, the indications the committee actually considered are narrow and clinical, including ulcerative colitis, wound healing and insomnia, and they are not the recovery, longevity and performance framing that most consumer marketing runs on. Third, the evidence problems the reviewers documented did not evaporate because a vote went the other way; for several of these substances there is still no human effectiveness data at all, and that is the honest state of the science as of this writing. If a seller tells you these peptides are now FDA-approved, that is false. They are not FDA-approved, and a committee recommendation is not approval. For where that leaves the legal standing of a particular compound, our explainer at /learn/is-my-peptide-legal-2026 sets out the framework this vote sits inside.^{[1, 2, 3]}

References & sources

1. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Meeting notice and agenda, listing the substances discussed each day and the uses evaluated for each, and stating that advisory committees make non-binding recommendations.
2. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Questions. The verbatim ballot questions, asking for each substance whether it should be placed on the list, put separately for free base and acetate forms.
3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Describes the three routes by which a compounder may use a bulk substance, the 503A bulks list itself, and the February 2019 final rule and September 2019 proposed rule.
4. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances. Reviewers concluded the evaluation criteria weigh against placing BPC-157 free base and BPC-157 acetate on the 503A Bulks List.
5. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of KPV-Related Bulk Drug Substances. Reviewers cited a lack of any effectiveness and safety information in humans, weighing against KPV free base and KPV acetate being added to the 503A Bulks List.
6. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of TB-500-Related Bulk Drug Substances. Reviewers cited a lack of any evidence of effectiveness, weighing against TB-500 free base and TB-500 acetate being added to the 503A Bulks List.
7. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of MOTS-c-Related Bulk Drug Substances. Reviewers cited a lack of any safety and effectiveness information in humans, weighing against MOTS-c free base and MOTS-c acetate being added to the 503A Bulks List.
8. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of Epitalon-Related Bulk Drug Substances. Reviewers cited limited information on historical use and a lack of evidence of effectiveness and safety, weighing against epitalon free base and epitalon acetate being added to the 503A Bulks List.
9. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of Semax-Related Bulk Drug Substances. Reviewers cited a lack of evidence of effectiveness, weighing against semax free base and semax acetate being added to the 503A Bulks List.
10. U.S. Food and Drug Administration. FDA Briefing Document, PCAC Meeting July 23-24, 2026: Evaluation of Emideltide-Related Bulk Drug Substances. Reviewers concluded that physicochemical characterization, historical use, evidence of effectiveness and safety information all weigh against emideltide free base and emideltide acetate being added to the 503A Bulks List.